No Data
No Data
Shandong Jincheng Pharmaceutical Group (SZSE:300233) Shareholders Are up 7.9% This Past Week, but Still in the Red Over the Last Three Years
Jincheng Pharmaceutical (300233.SZ): Jincheng Taier obtained CEP certificate for bisoprolol fumarate chemical raw material
On July 26th, Glonhe announced that its wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd. (referred to as "Jincheng Tail"), received a Certificate of Suitability for a Monograph of the European Pharmacopoeia (CEP Certificate) issued by the European Directorate for the Quality of Medicines (EDQM) for the chemical raw material, bisoprolol fumarate. Bisoprolol fumarate is a highly selective β1-adrenergic receptor blocker mainly used to treat hypertension, coronary heart disease, and chronic heart failure. Bisoprolol fumarate was developed by Merck in Germany and was launched in Germany in 1986 in tablet form as a commodity.
Shandong Jincheng Pharmaceutical Group (300233.SZ): One of the actual controllers, Zhao Hongfu, plans to reduce his shareholding by no more than 3 million shares.
On July 12th, Gelunhui reported that Mr. Zhao Hongfu, one of the actual controllers, plans to reduce his shareholding in the company by no more than 3 million shares within 3 months after 15 trading days from the disclosure of this announcement through centralized bidding and bulk trading, accounting for no more than 0.7909% of the total share capital excluding the shares held in the company's repurchase account.
China Approves Changes to Shandong Jincheng's Antibiotic; Shares Up 3%
Shandong Jincheng Pharmaceutical Group (300233.SZ): the drug supplement application approval notice for injection of Cefoperazone sodium and Sulbactam sodium has been received.
On July 10th, Gelunhui reported that Shandong Jincheng Pharmaceutical Group (300233.SZ), the holding subsidiary, recently received a "Drug Supplementary Application Approval Notice" for injection cephalosporin and sulbactam sodium issued by the National Drug Administration. Injection cephalosporin and sulbactam sodium is a compound preparation composed of the third-generation cephalosporin and beta-lactamase inhibitor, which can be used alone to treat upper and lower respiratory tract infections caused by sensitive bacteria; upper and lower urinary tract infections; peritonitis, cholecystitis, cholangitis and other intra-abdominal infections; sepsis; meningitis; skin and soft tissue infections; bone and...
Shandong Jincheng Pharmaceutical Group (stock code: 300233.SZ): Injection Chloramphenicol Sodium Succinate obtained drug registration certificate.
Jincheng Pharmaceutical (300233.SZ) announced that its wholly-owned subsidiary Beijing Jincheng Teal Pharmaceuticals Co., Ltd. (referred to as "Jincheng Teal") has received an injection registration certificate for chlorpromazine issued by the National Medical Products Administration (Certificate Number: 2024S01517). The injection of chlorpromazine is registered as a Class 4 chemical drug and was approved based on the consistency evaluation of generic drug quality and efficacy. According to the website of the National Medical Products Administration, chlorpromazine is currently available in China in injection and tablet forms and is mainly used for short-term treatment of moderate to severe pain after surgery.
No Data